Sean Grant - 03 Apr 2024 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
03 Apr 2024
Net transactions value
-$3,205,279
Form type
4
Filing time
05 Apr 2024, 21:32:12 UTC
Previous filing
18 Jan 2024
Next filing
20 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $1,484,442 +99,828 +150% $14.87* 166,165 03 Apr 2024 Direct F1
transaction VERA Class A Common Stock Sale $2,796,801 -69,831 -42% $40.05 96,334 03 Apr 2024 Direct F2
transaction VERA Class A Common Stock Sale $424,708 -10,988 -11% $38.65 85,346 03 Apr 2024 Direct F3
transaction VERA Class A Common Stock Sale $444,080 -11,648 -14% $38.12 73,698 03 Apr 2024 Direct F4
transaction VERA Class A Common Stock Sale $288,927 -7,361 -10% $39.25 66,337 03 Apr 2024 Direct F5
transaction VERA Class A Common Stock Sale $2,979 -78 -23% $38.20 257 03 Apr 2024 By Roth IRA F6
transaction VERA Class A Common Stock Sale $3,137 -80 -31% $39.22 177 03 Apr 2024 By Roth IRA F7
transaction VERA Class A Common Stock Sale $7,090 -177 -100% $40.06 0 03 Apr 2024 By Roth IRA F8
transaction VERA Class A Common Stock Sale $14,793 -387 -24% $38.22 1,233 03 Apr 2024 As custodian for UTMA account F6, F9, F10
transaction VERA Class A Common Stock Sale $14,342 -366 -30% $39.18 867 03 Apr 2024 As Custodian for UTMA account F7, F9, F10
transaction VERA Class A Common Stock Sale $34,731 -867 -100% $40.06 0 03 Apr 2024 As Custodian for UTMA account F8, F9, F10
transaction VERA Class A Common Stock Sale $25,686 -672 -24% $38.22 2,144 03 Apr 2024 By IRA F6
transaction VERA Class A Common Stock Sale $25,044 -639 -30% $39.19 1,505 03 Apr 2024 By IRA F7
transaction VERA Class A Common Stock Sale $60,286 -1,505 -100% $40.06 0 03 Apr 2024 By IRA F8
transaction VERA Class A Common Stock Sale $7,684 -201 -23% $38.23 656 03 Apr 2024 By Spouse's IRA F6
transaction VERA Class A Common Stock Sale $7,957 -203 -31% $39.20 453 03 Apr 2024 By Spouse's IRA F7
transaction VERA Class A Common Stock Sale $18,144 -453 -100% $40.05 0 03 Apr 2024 By Spouse's IRA F8
transaction VERA Class A Common Stock Sale $118,950 -3,112 -17% $38.22 14,909 03 Apr 2024 By Trust F6
transaction VERA Class A Common Stock Sale $115,384 -2,944 -20% $39.19 11,965 03 Apr 2024 By Trust F7
transaction VERA Class A Common Stock Sale $278,997 -6,965 -58% $40.06 5,000 03 Apr 2024 By Trust F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Options Exercise $0 -99,828 -55% $0.000000 80,172 03 Apr 2024 Class A Common Stock 99,828 $14.87 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,939 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2024.
F2 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.36, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.25 to $39.225, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.52, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.075 to $39.35, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F6 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.70 to $38.64, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F7 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.75 to $39.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F8 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.82 to $40.355, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F9 The shares were acquired through a custodial account established for an immediate family member of the Reporting Person pursuant to the Uniform Transfers to Minors Act, for which the Reporting Person serves as a custodian.
F10 The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
F11 1/4 of 180,000 shares subject to the option vested on July 12, 2022, and 1/48 of the shares vest monthly thereafter.